Global Plasma Fractionation Market Size Share Trends and Forecast 2034
Global Plasma Fractionation Market Size Share Trends and Forecast 2034
The Plasma fractionation market share in 2026 is a crucial biopharmaceutical process used to separate plasma proteins from human blood plasma for therapeutic use. These proteins, including immunoglobulins, albumin, coagulation factors, and protease inhibitors, play a vital role in treating immune deficiencies, neurological disorders, and bleeding conditions. The rising awareness regarding plasma donation and advancements in fractionation technologies are further accelerating market growth globally.
According to Fortune Business Insights, the global plasma fractionation market size was valued at USD 40.27 billion in 2025 and is projected to grow from USD 43.55 billion in 2026 to USD 87.23 billion by 2034, exhibiting a CAGR of 9.1% during the forecast period. North America dominated the plasma fractionation market with a market share of 56.22% in 2025. The increasing prevalence of rare and chronic diseases, along with growing demand for plasma-derived therapies, is significantly contributing to market expansion.
CSL (Australia)
Grifols, S.A. (Spain)
Takeda Pharmaceutical Company Limited (Japan)
Octapharma AG (Switzerland)
Kedrion S.p.A. (Italy)
LFB Group (France)
ADMA Biologics, Inc. (U.S.)
GC Biopharma (South Korea)
Beijing Tiantan Biological Products Co., Ltd. (China)
Shanghai RAAS Blood Products Co., Ltd. (China)
The plasma fractionation market is primarily driven by the rising incidence of immunological and neurological disorders, which require plasma-derived therapies for effective treatment. Increasing use of immunoglobulins in treating primary immunodeficiency diseases and autoimmune conditions is boosting product demand. Additionally, the growing aging population and rising healthcare expenditure are further supporting market growth.
Technological advancements in plasma collection and fractionation processes have improved yield efficiency and product safety, encouraging pharmaceutical companies to expand their manufacturing capacities. Furthermore, increasing government initiatives and awareness programs related to plasma donation are positively influencing market development.
However, the market faces certain restraints, including stringent regulatory requirements for plasma collection and processing. High costs associated with plasma fractionation infrastructure and dependency on plasma donors may limit market growth. Additionally, supply chain challenges and limited availability of plasma in certain regions could hinder expansion.
The plasma fractionation market report provides a comprehensive analysis of key industry trends, growth drivers, restraints, and opportunities. It offers detailed insights into market size, share, and forecast, along with an in-depth evaluation of competitive dynamics. The report also highlights technological advancements, regulatory frameworks, and strategic initiatives undertaken by major players.
It includes segmentation analysis based on product type, application, and end-user, providing a holistic understanding of market performance. Additionally, the report covers regional trends and identifies growth opportunities across major geographies, enabling stakeholders to make informed business decisions.
The competitive landscape of the plasma fractionation market is characterized by the presence of established global players focusing on capacity expansion and product innovation. Companies are investing in advanced fractionation technologies and expanding their plasma collection networks to strengthen their market position.
Strategic collaborations, mergers, and acquisitions are commonly adopted by key players to enhance their product portfolios and geographic presence. Continuous research and development activities aimed at improving the efficacy and safety of plasma-derived therapies are further intensifying competition in the market.
The plasma fractionation market is segmented based on
By Product (Albumin, Immunoglobulin {IVIG and SCIG}, Coagulation Factors {Factor IX, Factor VIII, and von Willebrand Factor}, and Protease Inhibitors {Alpha-1 Antitrypsin and C1 Esterase Inhibitor})
By Application (Immunology, Neurology, Hematology, Critical Care, and Pulmonology)
By End User (Hospitals & Clinics, Specialty Clinics & Infusion Centers, and Homecare Settings)
Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/industry-reports/plasma-fractionation-market-101614
North America holds the largest share of the plasma fractionation market, supported by well-established healthcare infrastructure, high awareness regarding plasma donation, and strong presence of leading market players. The region’s dominance is further reinforced by favorable reimbursement policies and advanced research capabilities.
Europe represents another significant market, driven by increasing adoption of plasma-derived therapies and supportive regulatory frameworks. Countries in this region are focusing on improving plasma collection efficiency and expanding manufacturing facilities.
Asia Pacific is expected to witness substantial growth during the forecast period due to rising healthcare investments, growing patient population, and increasing awareness regarding plasma-based treatments. Emerging economies in the region are investing in healthcare infrastructure, creating lucrative opportunities for market expansion.
The future of the plasma fractionation market looks promising, with continuous advancements in biotechnology and increasing demand for personalized medicine. Growing focus on improving plasma collection techniques and expanding donor pools is expected to enhance supply availability.
Innovation in fractionation technologies and the development of novel plasma-derived products will further drive market growth. Additionally, increasing collaborations between public and private sectors are anticipated to accelerate research and development activities.
With rising awareness about the importance of plasma-derived therapies and expanding applications across various medical fields, the plasma fractionation market is set to witness sustained growth in the coming years. Companies are expected to focus on strengthening their global footprint and enhancing production capabilities to meet the growing demand.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free),
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com